By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for Seltorexant
Email this page to a colleague
What is the drug development status for Seltorexant?
Seltorexant is an investigational drug.
There have been 11 clinical trials for Seltorexant.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 31st 2020.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Janssen Research & Development, LLC, Minerva Neurosciences, and [disabled in preview].
There are four US patents protecting this investigational drug and fifty-nine international patents.
Summary for Seltorexant
| US Patents | 4 |
| International Patents | 59 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-08-31) |
| Vendors | 9 |
Recent Clinical Trials for Seltorexant
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants | Janssen Research & Development, LLC | Phase 1 |
| A Study of Seltorexant in Healthy Participants | Janssen Research & Development, LLC | Phase 1 |
| A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With S | Janssen Research & Development, LLC | Phase 3 |
Clinical Trial Summary for Seltorexant
Top disease conditions for Seltorexant
Top clinical trial sponsors for Seltorexant
US Patents for Seltorexant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Seltorexant | Get Started Free | Methods of treating depression using orexin-2 receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | Get Started Free |
| Seltorexant | Get Started Free | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica (BE) | Get Started Free |
| Seltorexant | Get Started Free | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV (BE) | Get Started Free |
| Seltorexant | Get Started Free | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV (Beerse, BE) | Get Started Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Seltorexant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Seltorexant | Argentina | AR078731 | 2029-10-23 | Get Started Free |
| Seltorexant | Argentina | AR114667 | 2029-10-23 | Get Started Free |
| Seltorexant | Australia | AU2010310595 | 2029-10-23 | Get Started Free |
| Seltorexant | Australia | AU2015242975 | 2029-10-23 | Get Started Free |
| Seltorexant | Brazil | BR112012010820 | 2029-10-23 | Get Started Free |
| Seltorexant | Canada | CA2778484 | 2029-10-23 | Get Started Free |
| Seltorexant | Chile | CL2010001162 | 2029-10-23 | Get Started Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
